BAJAJ BROKING
Zydus Lifesciences’ Zynext Ventures invests in Feldan Therapeutics to enhance drug delivery systems. Feldan’s lead candidate FLD-103 targets skin cancer, while its pulmonary programme focuses on respiratory diseases. The deal strengthens Zydus' innovation pipeline.
Zynext Ventures, the venture capital arm of Zydus Lifesciences, has announced a strategic investment in Feldan Therapeutics, a Canadian clinical-stage pharmaceutical company. The collaboration is aimed at accelerating the development of targeted intracellular drug delivery systems. Feldan’s proprietary Shuttle peptide technology allows for the direct transport of therapeutic biomolecules into cells, enabling new treatment options for conditions where traditional drug delivery methods fall short.
Also read: BHEL Signs Tech Deal With BARC to Cut Green Hydrogen Costs
Zydus Lifesciences’ Zynext Ventures invests in Canada-based Feldan Therapeutics
Feldan’s Shuttle peptide enables biomolecule delivery into targeted cells
FLD-103 is being developed as a non-surgical treatment for basal cell carcinoma
A pulmonary pipeline targets unmet needs in respiratory disease treatment
Zydus strengthens its innovation portfolio through biotech investment
Also read: UltraTech Cement Acquires 26% Stake in Solar SPV for Rs.25.5 Crore
Feldan’s lead candidate, FLD-103, is being developed as a direct application therapy for basal cell carcinoma (BCC), the most common form of skin cancer. This drug is injected directly into BCC lesions, where the Shuttle peptide delivers a Hedgehog pathway inhibitor into the affected cells. This non-invasive approach offers a potential alternative to surgery and aims to improve patient recovery outcomes.
In addition to dermatological use, Feldan is advancing a pulmonary programme that applies its delivery technology to respiratory treatments. The unique ability of the Shuttle peptide to access difficult-to-penetrate lung cells opens up the possibility of developing therapies for complex respiratory conditions that currently lack effective solutions.
This investment reflects Zydus Lifesciences’ strategic intent to broaden its innovation pipeline and support emerging technologies in the global healthcare space. By backing Feldan Therapeutics, Zynext Ventures is reinforcing Zydus’ commitment to novel drug development with high-impact potential.
With this move, Zydus Lifesciences positions itself at the forefront of next-generation therapeutic platforms. As the partnership progresses, the clinical outcomes of Feldan’s research may influence the long-term trajectory of Zydus Lifesciences share price, given the rising investor interest in precision medicine and advanced delivery systems.
Aspect | Details |
Investing Company | Zynext Ventures (Zydus Lifesciences VC arm) |
Investee | Feldan Therapeutics (Canada) |
Technology Focus | Shuttle peptide for intracellular biomolecule delivery |
Lead Candidate | FLD-103 (targets basal cell carcinoma lesions) |
Other Pipeline | Pulmonary drug delivery for respiratory diseases |
Strategic Goal | Expand non-surgical therapies and improve intracellular drug delivery |
This investment strengthens Zydus Lifesciences’ commitment to pioneering healthcare innovation through strategic collaborations. With promising developments on the horizon, it could also positively impact the Zydus Lifesciences share price as markets respond to its innovation-focused roadmap.
Also read: DLF To Sell Kolkata IT SEZ To Srijan Group For Rs.693 Crore
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading